CClinicalTrials.gg
Status unknownNCT03802734PaMPPrUpdated Dec 9, 2019

Perinatal Effects of Mindfulness Phone App Use in Pregnancy (PaMPPr Study)

An interventional study of Mindful meditation phone app in Sleep and Pregnancy, sponsored by Unity Health Toronto. Status unknown at 1 site in Canada. Open to female participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-09.

Sponsored by Unity Health Toronto · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
16 Years and older
Sex
Female
01

Study summary

There is evidence to show that mindful meditation has a positive impact on health. To date, all the studies done to investigate the effect of mindfulness on pregnancy outcomes have been done through a traditional 8-10 weeks mindfulness classroom program with some home practice. This time-intensive classroom training may be expensive and not convenient for many busy pregnant women. This study will investigate the use of a smartphone app-based intervention to determine if it has the potential to make mindfulness training more accessible, acceptable, and convenient to a larger number of pregnant women. The use of an app as opposed to traditional structured classes may increase a woman's ability and willingness to practice mindfulness because the app can be used almost anywhere and at any time. This pilot study aims to explore the feasibility and acceptability of a smartphone mindfulness meditation application for pregnant women. As well, this study will compare the pregnancy outcomes of women who use the app to those women who do not use the app.

Read the detailed description

This is a randomised controlled trial to study the effect of the use of a mindfulness meditation app on pregnancy outcomes. This study will measure how often the app is used, as well as indicators of maternal health such as sleep, stress, depression, anxiety and other perinatal outcomes (premature delivery, diabetes during pregnancy (gestational diabetes), high blood pressure in pregnancy (hypertensive disorders of pregnancy), inadequate growth of the baby inside the womb (fetal growth restriction), bleeding in later pregnancy, mode of delivery, pain relief during delivery, length of stay for mother and baby in the hospital, admission of baby in ICU, pain relief medication requirement after delivery, and breastfeeding).

Participants will be randomly assigned to either group A (the experimental group) or group B (the control group). All participants will be given a an actigraph to measure sleep.

Participants in Group A will be given a free subscription to a mindfulness meditation app for six months. They will also be given a general pregnancy sleep leaflet. Participants assigned to Group B will be given the general pregnancy sleep leaflet only.

There will be 3 visits associated with this study. At each of the 3 visits, participants will be given four questionnaires to complete - the Pittsburgh Sleep Quality Index, Perceived Stress Questionnaire, Beck's Anxiety Inventory, and the Edinburgh Postnatal Depression Scale. Participants in Group A will also be asked to complete a fifth survey at their post-partum visit. This survey will collect information on how easy it was to use the mindfulness meditation app.

Information on delivery outcomes will also be collected. This information will include things such as any complications that occur during delivery, baby's birth weight and Apgar score, any complications with baby's health, method of delivery, and pain medications used during delivery.

02

Conditions studied

  • Sleep
  • Pregnancy
03

In context

Lead sponsor

Unity Health Toronto is the lead sponsor of 434 studies on the registry; 76 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Are able to understand and sign this consent form
  • Have a singleton pregnancy (not having twins)
  • Are planning to give birth at St. Michael's Hospital
  • Have access to personal email, a smartphone, and have a data plan
  • Are able to understand and write English
  • Are 20-30 weeks into your pregnancy

Exclusion criteria

Exclusion Criteria:

  • Are formally practicing a body-mind activity (except yoga) or currently using a mindfulness/meditation app
  • Have a known psychiatric diagnosis or acute psychiatric illness (substance dependence or abuse, history of schizophrenia or other psychotic disorders, eating disorders, etc.)
  • Have a mood disorder and/or suicide risk
  • Have any medical, infectious, or degenerative disease that may affect mood, behavior, and stress levels
  • Have a known fetal anomaly
  • Have an uncontrolled medical condition that may interfere with sleep or requires immediate treatment
  • Have a comorbid sleep disorder, including obstructive sleep apnea, restless legs syndrome, or circadian rhythm sleep disorders
  • Are using hypnotic or sedating medications, antidepressant or antipsychotic medications, or currently under psychopharmacological, behavioral, or psychoanalytic treatment
  • Are a night shift worker
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Mindful Meditation App

    Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.

    Device: Mindful meditation phone app

  • No intervention
    No Meditation App

    Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.

Interventions

  • DeviceMindful meditation phone app

    Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.

06

What researchers measure

Primary outcomes

  1. Sleep

    Sleep/wake cycles as measured by an accelerometer that measures tri-axial movement (i.e., actigraphy) for qualitative assessment of sleep.

    Time frame: 20 weeks gestation to 6 weeks post partum

  2. Use of Meditation Phone App - minutes per day

    Measured use of the Headspace app in minutes per day

    Time frame: 20 weeks gestation to 6 weeks post partum

  3. Use of Meditation Phone App - sessions completed

    Measured use of the Headspace app in total number of sessions completed

    Time frame: 20 weeks gestation to 6 weeks post partum

  4. Use of Meditation Phone App - type of sessions

    Breakdown of the number of different session-types used

    Time frame: 20 weeks gestation to 6 weeks post partum

  5. Use of Meditation Phone App - average session length

    Average session length (in minutes)

    Time frame: 20 weeks gestation to 6 weeks post partum

  6. Use of Meditation Phone App - total time spent meditating

    Total number of minutes spent meditating using the meditation phone app

    Time frame: 20 weeks gestation to 6 weeks post partum

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Participants will rate the frequency of sleep disturbances on a 4-point Likert scale (0 = "Not during the past month"; 1 = "Less than once a week"; 2 = "Once or twice a week"; 3 = "Three or more times a week". Scores will be tallied. A score of 5 or more indicates poor sleep quality. Scores will be compared across 3 time-points.

    Time frame: PSQI will be completed at 3 time-points: <= 20 weeks gestation, 35-40 weeks gestation, 6 weeks post-partum.

  2. Perceived Stress Scale (PSS)

    Participants will rate the frequency of certain thoughts and feelings over the past month on a 5-point Likert scale (0 = "Never"; 1 = "Almost never"; 2: "Sometimes"; 3: "Fairly often"; 4: "Very often". Scores will be tallied using the special PSS scoring system. Scores will be compared across 3 time-points.

    Time frame: PSS will be completed at 3 time-points: <= 20 weeks gestation, 35-40 weeks gestation, 6 weeks post-partum.

  3. Edinburgh Postnatal Depression Scale (EPDS)

    This scale measures post-natal and prenatal depression by asking participants to rate how they have felt emotionally during the last 7 days. Various 4-point Likert scales are used to measure the frequency of occurance (e.g. 0 = No never, 1 = Not very often, 2 = Yes, some of the time, 3 = Yes, most of the time). Scores will be tallied to measure level of depression. Higher scores indicate higher levels of post-natal depression. Scores will be compared across 3 time-points.

    Time frame: EDPS will be completed at 3 time-points: <= 20 weeks gestation, 35-40 weeks gestation, 6 weeks post-partum.

  4. Beck Anxiety Inventory (BAI)

    Participants will indicate the frequency of anxiety symptoms during the past month on a 4-point Likert scale (0 = No not at all, 1 = Mildly, but it didn't bother me much, 2 = Moderately, it wasn't pleasant at times, 3 = Severely, it bothered me a lot). Scores will be tallied to indicate severity of anxiety. Higher scores indicate higher levels of anxiety. Scores will be compared across 3 time-points.

    Time frame: 20 weeks gestation to 6 weeks post partum

  5. Complications during pregnancy

    Complications during pregnancy will be recorded using information collected directly from the participant and information collected from their medical chart.

    Time frame: Beginning of pregnancy to delivery

  6. Complications during delivery

    Complications during delivery will be recorded using information collected from the patient's medical chart.

    Time frame: Delivery

07

Study locations

1 site
  • St. Michael's Hospital
    Toronto, Ontario M5B1W8, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03802734
Lead sponsor
Unity Health Toronto
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Aug 15, 2019
Primary completion
Jan 2, 2021 (estimated)
Completion
Jan 2, 2021 (estimated)
Last update
Dec 9, 2019

Study contacts

Howard Berger, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion